Acalculous cholecystitis

Summary

Acalculous cholecystitis (MONDO:0006633) is a disease and 5 clinical trials. Top therapeutic interventions include ezetimibe. A subtype of cholecystitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acalculous cholecystitis
Mondo ID	MONDO:0006633
EFO	EFO:1000790
MeSH	D042101
DOID	DOID:2828
NCIT	C35578
SNOMED CT	19968009
UMLS	C0267841
MedGen	82762
MedDRA	10000347
Is cancer (heuristic)	no

Also known as: acute acalculous cholecystitis

Disease family

This is a subtype of cholecystitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › non-neoplastic bile duct disorder › cholangitis › cholecystitis › acalculous cholecystitis

Related subtypes (3): xanthogranulomatous cholecystitis, emphysematous cholecystitis, acute cholecystitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00634140	Not specified	WITHDRAWN	The Influence of Ezetimibe on Gallbladder Function
NCT01894321	Not specified	COMPLETED	The Clinical Outcomes of the Percutaneous Cholecystostomy, Supportive Care Versus Cholecystectomy.
NCT05587933	Not specified	UNKNOWN	Ejection Fraction of Normal Gall Bladder on Ultrasonography in Patients With Biliary Colic: Is it a Predictor of Cholecystectomy?
NCT06178848	Not specified	COMPLETED	EEG Parameters Between Remimazolam- and Propofol-based Anesthesia
NCT06191471	Not specified	COMPLETED	Hepatitis A Virus Induced Acute Acalculous Cholecystitis Diagnosed Postoperatively: Case Report

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EZETIMIBE	4	1